• Luxempart increased its stake in Medios to more than 20%, reinforcing its long-term healthcare investment strategy.
• The investment firm became an anchor shareholder in June 2024 by acquiring a stake from Medios’ founder.
• Medios is a listed European pharmaceutical services group operating in specialty pharmaceutical supply and compounding.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Luxempart SA published the original content used to generate this news brief on November 02, 2026, and is solely responsible for the information contained therein.